Exploration of the value of MRCP combined with tumor marker CA19-9 in the diagnosis of pancreatic cancer

Figures & data

Table I. General status of age in the MRCP-combined group and the MRCP-only group.

	MRCP-combined group (N = 70)		MRCP-only group (N = 48)
	$$\overline{x}\pm S$$	Max/Min	$$\overline{x}\pm S$$	Max/Min
Age	65.8 ± 12.8	83/34	63.5 ± 11.7	82/39

Table II. Gender distribution status of the MRCP-combined group and MRCP-only group.

	MRCP-combined group (N = 70)		MRCP-only group (N = 48)
Gender
Male	47	72.8%	33	68.8%
Female	23	37.2%	15	31.2%

Figure 1. MRCP examination.

Table III. The comparison of MRCP combined with CA19-9 for the diagnosis of pancreatic cancer.

	Total	Positive	Positive rate	P
MRCP combined with CA19-9	70	67	95.7%	P < 0.05
MRCP alone	48	44	91.7%

Figure 2. The positive rate of pancreatic cancer diagnosis in MRCP combined group and MRCP group.

Figure 3. The initial symptoms of pancreatic cancer.